SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs upcoming decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders citing the amended upper-limb data, rare-disease policy discussions and recent launch-related hiring as reasons for optimism. Others caution that approval is uncertain given the prior negative review and continuing questions about the evidence.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a treatment for recurrent respiratory papillomatosis has renewed focus on competition for Precigens PAPZIMEOS. Traders debate whether the new entrant threatens Precigens first-mover commercial lead or whether the selloff overstates the risk, citing differences in approval status, clinical data and commercialization challenges.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 leukemia trial reaching its prespecified 80th death event has put final analysis and the topline readout in focus. Traders are sharply divided: bulls expect GPS to show a survival benefit, while skeptics question the trial assumptions and whether it can outperform the physicians-choice arm; shares have sold off despite the milestone.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths post-TDAPA Medicare add-on could fall sharply after Q1 2027 has fueled concerns about pricing and CorMedix revenue amid a steep selloff. Traders dispute whether DaVitas preliminary outlook signals a broader reimbursement decline, pointing to CMSs published estimate, while others criticize management for not clarifying the potential impact.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A rally to fresh 52-week highs ahead of anticipated Q3 earnings has traders focused on whether BRIUMVI growth can support the move, while unconfirmed buyout speculation and short-squeeze talk add to the excitement. Some traders attribute the gains to earnings expectations rather than a potential acquisition.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp technology and AI-linked selloffintensified by Intels weak outlook and concerns about returns on heavy AI investmentis driving attention to QQQ. Traders are split between warning of more downside and treating the drop as an oversold dip with potential for a rebound.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is drawing attention after a sharp selloff, with traders citing weakness in expensive SaaS stocks and concerns about competition and valuation; some also point to CTO Alexis Le-Quocs disclosed share sale, which was made under a prearranged 10b5-1 plan. Views are split between dip-buyers and traders expecting further downside.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is drawing attention after a sharp gold selloff pushed the ETF to a 52-week low, with traders citing inflation concerns and expectations of higher interest rates as pressure on precious metals. The community is split between bearish calls for further declines and buyers viewing the pullback as a potential bottom, while many question why gold has not acted as a safe haven during broader market weakness.

Carnival Corp. Ltd. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corporation Ltd.

Carnival Corp

Carnivals quarterly earnings beat and raised full-year outlook, backed by record bookings and customer deposits, sparked a sharp rally and upbeat discussion about cruise demand. Some traders remain cautious about elevated fuel costs, softer near-term guidance, and debt.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, powered by Eylea HD sales and Sanofi collaboration revenue tied to Dupixent, are driving the sharp move. Traders are broadly positive about the earnings beat and breakout, while discussing whether newer medicines and pipeline programs can sustain growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


quatdienchatluong

Quạt Điện Chất Lượng